Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: A secondary analysis

Postgraduate Medicine

Volumn 120, Issue 3, 2008, Pages 89-102

  Lopez, Frank A ^a   Ginsberg, Lawrence D ^b   Arnold, Valerie ^c  

^a Children's Developmental Center   (United States)

^b Red Oak Psychiatry Associates   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

ADHD; Attention deficit hyperactivity disorder; Duration; Lisdexamfetamine dimesylate; Prodrug medication; Stimulant medication

Indexed keywords

LISDEXAMFETAMINE; PLACEBO; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE;

APPETITE DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BODY WEIGHT; CHILD; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERACTIVITY; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPPOSITIONAL DEFIANT DISORDER; PARENT; PATIENT COMPLIANCE; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK ASSESSMENT; SECONDARY ANALYSIS; SIDE EFFECT; TIME; UPPER ABDOMINAL PAIN; VOMITING; FOLLOW UP; PHASE 3 CLINICAL TRIAL; PSYCHOLOGIC TEST; PSYCHOLOGICAL ASPECT; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DEXTROAMPHETAMINE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PARENTS; PSYCHOLOGICAL TESTS; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

EID: 56149110887     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2008.09.1910     Document Type: Article

References (42)

1. Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA. 1998;279(14):1100-1107.
2. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366(9481):237-248. (Pubitemid 40981053)
3. Spencer TJ, Biederman J, Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol. 2007;32(6):631-642. (Pubitemid 47356045)
4. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004; 27(2):187-201. (Pubitemid 38452762)
5. Barkley RA, Murphy KR, DuPaul GJ, Bush T. Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc. 2002;8(5):655-672. (Pubitemid 34928352)
6. CME Institute of Physicians Postgraduate Press, Inc. Managing ADHD in children, adolescents, and adults with comorbid anxiety. J Clin Psychiatry. 2007;68(3):451-462.
7. Schatz DB, Rostain AL. ADHD with comorbid anxiety: a review of the current literature. J Atten Disord. 2006;10(2):141-149.
8. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999;56(12):1073- 1086.
9. Biederman J, Mick E, Faraone SV, et al. Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry. 2002;159(1):36-42. (Pubitemid 41070724)
10. Biederman J, Spencer TJ, Newcom JH, et al. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data. Psychopharmacology (Berl). 2007;190(1):31-41. (Pubitemid 44885341)
11. Diamond IR, Tannock R, Schachar RJ. Response to methylphenidate in children with ADHD and comorbid anxiety. J Am Acad Child Adolesc Psychiatry. 1999;38(4):402-409. (Pubitemid 29153111)
12. Pliszka SR. Effect of anxiety on cognition, behavior, and stimulant response in ADHD. J Am Acad Child Adolesc Psychiatry. 1989; 28(6):882-S87. (Pubitemid 20031022)
13. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921. (Pubitemid 46975925)
14. Pliszka SR, Crismon ML, Hughes CW, et al; Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-Deficit/ Hyperactivity Disorder. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention- deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(6):642-657.
15. American Academy of Pediatrics Subcommittee on Attention-Deficit/ Hyperactivity Disorder Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention- deficit/hyperactivity disorder. Pediatrics. 2001;108(4):1033-1044.
16. Stein MA, Baren M. Welcome progress in the diagnosis and treatment of ADHD in adolescence. Contemp Pediatr. 2003;20(8):83-110.
17. Stockl KM, Hughes TE, Jarrar MA, Secnik K, Perwien AR. Physician perceptions of the use of medications for attention deficit hyperactivity disorder. J Manag Care Pharm. 2003;9(5):416-423.
18. Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo- controlled, crossover analog classroom study. Biol Psychiatry. 2007;62(9):970-976. (Pubitemid 47562371)
19. Findling RL. Parental perceptions of the duration of effectiveness of prescription medications used to treat attention-deficit/hyperactivity disorder in children and adolescents. Poster presented at: 20th Annual US Psychiatric and Mental Health Congress; October 11-14, 2007; Orlando, FL. Poster 102.
20. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29(3):450-463. (Pubitemid 46924786)
21. Shojaei A, Ermer JC, Krishnan S. Lisdexamfetamine dimesylate as a treatment for ADHD: dosage formulation and pII effects. Poster presented at: the 160th Annual Meeting of the American Psychiatric Association; May 19-24, 2007; San Diego, CA. Poster NR 740.
22. Jasinski DR, Krishnan S. Abuse liability of intravenous L-lysine-d- amphetamine (NRP104). Presented at: College on Problems of Drug Dependence 68th Annual Scientific Meeting; June 17-22, 2006; Scottsdale, AZ. Abstract 365.
23. Findling RL, Childress AC, Krishnan S, McGough JJ. Long-term efficacy and safety of lisdexamfetamine in school-age children with attention-deficit/ hyperactivity disorder. Poster presented at: 160th Annual Meeting of the American Psychiatric Association: May 19-24, 2007; San Diego, CA. Poster NR 739.
24. Wigal SB, Gupta S, Guinta D, Swanson JM. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull. 1998;34(1):47-53. (Pubitemid 28176301)
25. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS® methylphenidate once a day in children with attention- deficit/hyperactivity disorder. Pediatrics. 2001;108(4):883-892. (Pubitemid 32947657)
26. Wigal S, Swanson JM, Feifel D, et al. A double-blind, placebo- controlled trial of dexmethylphenidate hydrochloride and d.l-threo-methylphenidate hydrochloride in children with attention- deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2004;43(11):1406-1414. (Pubitemid 39411041)
27. Biederman J, Lopez FA, Boellner SW, Chandler MC. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR®) in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110(2 pt 1):258-266. (Pubitemid 34833008)
28. Faraone SV. Understanding the effect size of ADHD medications: implications for clinical care. http://www.medscape.com/viewarticle/461543. Accessed November 19, 2007.
29. Faraone SV. Understanding effect size: how it's measured and what it means. http://www.medscape.com/viewarticle/569729. Accessed March 18, 2008.
30. Cohen J. Quantitative methods in psychology: a power primer. Psychol Bull. 1992;112(1):155-159.
31. Klassen AF, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics. 2004;114(5):c541-c547. (Pubitemid 41655750)
32. Biederman J, Faraone SV, Monuteaux MC, Grossbard JR. How informative are parent reports of attention-deficit/hyperactivity disorder symptoms for assessing outcome in clinical trials of long-acting treatments? A pooled analysis of parents' and teachers' reports. Pediatrics. 2004;113(6):1667-1671. (Pubitemid 38697974)
33. Conners CK, Sitarenios G, Parker JDA, Epstein JN. The Revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26(4):257-268. (Pubitemid 28359774)
34. Conners CK. Conners' Rating Scales Revised Technical Manual. North Tonawanda, NY: Multi-Health Systems Inc; 2001.
35. Swanson JM, Greenhill LL, Lopez FA, et al. Modafinil film-coated tablets in children and adolescents wilh attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry. 2006;67(1):137-147. (Pubitemid 43213294)
36. Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention- deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics. 2005;116(6): e777-e784. (Pubitemid 46056456)
37. Biederman J, Quinn D, Weiss M, et al. Efficacy and safety of Ritalin® LA, a new, once daily, extended-release dosage fonn of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr Drugs. 2003;5(12):833-841. (Pubitemid 38030609)
38. Connor DF, Steingard RJ. New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential. CNS Drugs. 2004;18(14):1011-1030. (Pubitemid 39612011)
39. Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry. 2001;40(2):147-158. (Pubitemid 32111018)
40. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
41. Scahill L, Schwab-Stone M. Epidemiology of ADHD in school-age children. Child Adolesc Psychiatr Clin N Am. 2000;9(3):541-555, vii. (Pubitemid 30620543)
42. Banaschewski T, Roessner V, Diltmann RW, Santosh PJ, Rothenberger A. Non-Stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry. 2004;13(suppl 1):1102-1116. (Pubitemid 39165256)